NCT05817292

Brief Summary

Characterization of the vaginal microbiota of women under fertile age and study of correlations with gynecological disorders

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2022

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 29, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2022

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

March 21, 2023

Completed
28 days until next milestone

First Posted

Study publicly available on registry

April 18, 2023

Completed
Last Updated

April 18, 2023

Status Verified

April 1, 2023

Enrollment Period

4 months

First QC Date

March 21, 2023

Last Update Submit

April 4, 2023

Conditions

Outcome Measures

Primary Outcomes (4)

  • Microbiota

    Change from baseline in the composition of the vaginal microbiota with the increase of the cell density of lactobacilli (at least 3 log units) and decrease of pathogens (at least 2 log units) at the end of the treatment (10 days) and during the wash-out period (4 weeks after the end of the treatment)

    Baseline; end of the treatment (10 days) ; wash-out (4 weeks)

  • Signs

    Change from baseline of Amsel's criteria at the end of the treatment (10 days) and during the wash-out period (4 weeks after the end of the treatment)

    Baseline; end of the treatment (10 days) ; wash-out (4 weeks)

  • Signs

    Change from baseline of the Nugent score with values between 0 and 3 at the end of the treatment (10 days) and during the wash-out period (4 weeks after the end of the treatment)

    Baseline; end of the treatment (10 days) ; wash-out (4 weeks)

  • Symptomatology

    Change from baseline of vulvovaginal erythema/edema, vulvar discomfort, burning, and itching

    Baseline; end of the treatment (10 days) ; wash-out (4 weeks)

Secondary Outcomes (1)

  • Wellbeing

    Baseline; end of the treatment (10 days) ; wash-out (4 weeks)

Study Arms (2)

Probiotic

Assumption of commercially available supplements containing probiotics

Dietary Supplement: Probiotics

Control

No assumption of supplements containing probiotics

Other: No intervention

Interventions

ProbioticsDIETARY_SUPPLEMENT

Assumption of commercial probiotics

Probiotic

No assumption of probiotics

Control

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsWomen in fertile age
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

healthy volunteers with vaginal microbiota imbalance

You may qualify if:

  • Age between 18 and 45 years;
  • Presence of at least one vaginal sign or symptom (leucorrhoea, burning, itching, and subjective vaginal discomfort);
  • Presence of at least 3 Amsel criteria;
  • Nugent score ≥ 7;
  • lactobacillary grade ≥ 2 (LBG) (according to Donders classification);
  • presence of blastospores and/or pseudohyphae evaluated by fresh mount microscopy

You may not qualify if:

  • Age \< 18 years;
  • Nugent score \< 7;
  • presence of sexually transmitted disease due to Chlamydia, Neisseria gonorrhoeae, or Trichomonas vaginalis as well as specific cervico-vaginitis or severe vulvovaginal symptoms related to acute candidiasis;
  • Clinically apparent herpes simplex infection;
  • Human papillomavirus or human immunodeficiency virus infections;
  • Use of antibiotic, antifungal, probiotic, or immunosuppressive drugs during the past four weeks;
  • Use of vaginal contraceptives;
  • Pregnancy or breastfeeding, chronic diseases, neoplastic disease, diabetes, genital tract bleeding)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Catania

Catania, 95123, Italy

Location

Biospecimen

Retention: SAMPLES WITH DNA

vaginal discharge

MeSH Terms

Conditions

Vaginal Diseases

Interventions

Probiotics

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

Dietary SupplementsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Antonio Cianci, Prof

    University of Catania

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

March 21, 2023

First Posted

April 18, 2023

Study Start

February 1, 2022

Primary Completion

May 29, 2022

Study Completion

October 30, 2022

Last Updated

April 18, 2023

Record last verified: 2023-04

Locations